Cited 2 times in
Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김석모 | - |
dc.contributor.author | 박기청 | - |
dc.contributor.author | 윤혁준 | - |
dc.contributor.author | 임진홍 | - |
dc.date.accessioned | 2022-12-22T04:05:44Z | - |
dc.date.available | 2022-12-22T04:05:44Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192041 | - |
dc.description.abstract | Thyroid carcinoma, a disease in which malignant cells form in the thyroid tissue, is the most common endocrine carcinoma, with papillary thyroid carcinoma (PTC) accounting for nearly 80% of total thyroid carcinoma cases. However, the management of metastatic or recurrent therapy-refractory PTC is challenging and requires complex carcinoma therapy. In this study, we proposed a new clinical approach for the treatment of therapy-refractory PTC. We identified sarco/endoplasmic reticulum calcium ATPase (SERCA) as an essential factor for the survival of PTC cells refractory to the treatment with paclitaxel or sorafenib. We validated its use as a potential target for developing drugs against resistant PTC, by using patient-derived paclitaxel- or sorafenib-resistant PTC cells. We further discovered novel SERCA inhibitors, candidates 7 and 13, using the evolutionary chemical binding similarity method. These novel SERCA inhibitors determined a substantial reduction of tumors in a patient-derived xenograft tumor model developed using paclitaxel- or sorafenib-resistant PTC cells. These results could provide a basis for clinically meaningful progress in the treatment of refractory PTC by identifying a novel therapeutic strategy: using a combination therapy between sorafenib or paclitaxel and specific SERCA inhibitors for effectively and selectively targeting extremely malignant cells such as antineoplastic-resistant and carcinoma stem-like cells. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Agents* / pharmacology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoplasm Recurrence, Local / drug therapy | - |
dc.subject.MESH | Paclitaxel / pharmacology | - |
dc.subject.MESH | Paclitaxel / therapeutic use | - |
dc.subject.MESH | Phenylurea Compounds / pharmacology | - |
dc.subject.MESH | Phenylurea Compounds / therapeutic use | - |
dc.subject.MESH | Sorafenib / pharmacology | - |
dc.subject.MESH | Sorafenib / therapeutic use | - |
dc.subject.MESH | Thyroid Cancer, Papillary / drug therapy | - |
dc.subject.MESH | Thyroid Neoplasms* / pathology | - |
dc.title | Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Seok-Mo Kim | - |
dc.contributor.googleauthor | Keunwan Park | - |
dc.contributor.googleauthor | Jin Hong Lim | - |
dc.contributor.googleauthor | Hyeok Jun Yun | - |
dc.contributor.googleauthor | Sang Yong Kim | - |
dc.contributor.googleauthor | Kyung Hwa Choi | - |
dc.contributor.googleauthor | Chan Wung Kim | - |
dc.contributor.googleauthor | Jae Ha Lee | - |
dc.contributor.googleauthor | Raymond Weicker | - |
dc.contributor.googleauthor | Cheol-Ho Pan | - |
dc.contributor.googleauthor | Ki Cheong Park | - |
dc.identifier.doi | 10.3390/ijms231810378 | - |
dc.contributor.localId | A00542 | - |
dc.contributor.localId | A01449 | - |
dc.contributor.localId | A06022 | - |
dc.relation.journalcode | J01133 | - |
dc.identifier.eissn | 1422-0067 | - |
dc.identifier.pmid | 36142303 | - |
dc.subject.keyword | drug-resistant papillary thyroid carcinoma | - |
dc.subject.keyword | paclitaxel | - |
dc.subject.keyword | patient-derived xenograft tumor model | - |
dc.subject.keyword | sorafenib | - |
dc.contributor.alternativeName | Kim, Seok Mo | - |
dc.contributor.affiliatedAuthor | 김석모 | - |
dc.contributor.affiliatedAuthor | 박기청 | - |
dc.contributor.affiliatedAuthor | 윤혁준 | - |
dc.citation.volume | 23 | - |
dc.citation.number | 18 | - |
dc.citation.startPage | 10378 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, Vol.23(18) : 10378, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.